FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895582236> ?p ?o ?g. }

• W2895582236 endingPage "3889" @default.
• W2895582236 startingPage "3881" @default.
• W2895582236 abstract "Abstract BACKGROUND Cetuximab combined with radiation therapy (RT) is an evidence‐based treatment for locally advanced head and neck squamous cell carcinoma (HNSCC); however, locoregional failure remains the primary cause of cancer‐related death in this disease. Intratumoral injection of epidermal growth factor receptor (EGFR)‐antisense plasmid DNA (EGFR‐AS) is safe and has been associated with promising lesional responses in patients who have recurrent/metastatic HNSCC. For the current study, the authors investigated the antitumor effects of cetuximab and EGFR‐AS in preclinical HNSCC models and reported their phase 1 experience adding intratumoral EGFR‐AS to cetuximab RT. METHODS Antitumor mechanisms were investigated in cell line and xenograft models. Phase 1 trial eligibility required stage IVA through IVC HNSCC and a measurable lesion accessible for repeat injections. Patients received standard cetuximab was for 9 weeks. EGFR‐AS was injected weekly until they achieved a lesional complete response. RT was delivered by conventional fractionation for 7 weeks, starting at week 3. Research biopsies were obtained at baseline and week 2. RESULTS When added to cetuximab, EGFR‐AS decreased cell viability and xenograft growth compared with EGFR‐sense control, partially mediated by reduced EGFR expression. Six patients were enrolled in the phase 1 cohort. No grade 2 or greater EGFR‐AS–related adverse events occurred. The best lesional response was a complete response (4 patients), and 1 patient each had a partial response and disease progression. EGFR expression decreased in 4 patients who had available paired specimens. CONCLUSIONS In preclinical models, dual EGFR inhibition with cetuximab and EGFR‐AS enhanced antitumor effects. In a phase 1 cohort, intratumoral EGFR‐AS injections, cetuximab, and RT were well tolerated. A phase 2 trial is needed to conduct an extended evaluation of safety and to establish efficacy." @default.
• W2895582236 created "2018-10-12" @default.
• W2895582236 creator A5008924495 @default.
• W2895582236 creator A5014077632 @default.
• W2895582236 creator A5017526826 @default.
• W2895582236 creator A5017774152 @default.
• W2895582236 creator A5019997274 @default.
• W2895582236 creator A5028189327 @default.
• W2895582236 creator A5051070911 @default.
• W2895582236 creator A5051375932 @default.
• W2895582236 creator A5057744438 @default.
• W2895582236 creator A5066378974 @default.
• W2895582236 creator A5073246708 @default.
• W2895582236 creator A5086555588 @default.
• W2895582236 creator A5088286120 @default.
• W2895582236 date "2018-10-01" @default.
• W2895582236 modified "2023-10-14" @default.
• W2895582236 title "Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives" @default.
• W2895582236 cites W1534873232 @default.
• W2895582236 cites W1977340600 @default.
• W2895582236 cites W2005204942 @default.
• W2895582236 cites W2017788990 @default.
• W2895582236 cites W2019607817 @default.
• W2895582236 cites W2035857996 @default.
• W2895582236 cites W2062312459 @default.
• W2895582236 cites W2063721051 @default.
• W2895582236 cites W2067224845 @default.
• W2895582236 cites W2075981888 @default.
• W2895582236 cites W2089257078 @default.
• W2895582236 cites W2099764884 @default.
• W2895582236 cites W2105595995 @default.
• W2895582236 cites W2126983941 @default.
• W2895582236 cites W2147675788 @default.
• W2895582236 cites W2151730005 @default.
• W2895582236 cites W2153759214 @default.
• W2895582236 cites W2155384808 @default.
• W2895582236 cites W2159175023 @default.
• W2895582236 cites W2171547355 @default.
• W2895582236 cites W2194286561 @default.
• W2895582236 cites W2200765141 @default.
• W2895582236 cites W2235523093 @default.
• W2895582236 cites W2518025425 @default.
• W2895582236 cites W4255169631 @default.
• W2895582236 cites W1778748344 @default.
• W2895582236 doi "https://doi.org/10.1002/cncr.31651" @default.
• W2895582236 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6521720" @default.
• W2895582236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30291796" @default.
• W2895582236 hasPublicationYear "2018" @default.
• W2895582236 type Work @default.
• W2895582236 sameAs 2895582236 @default.
• W2895582236 citedByCount "6" @default.
• W2895582236 countsByYear W28955822362020 @default.
• W2895582236 countsByYear W28955822362022 @default.
• W2895582236 countsByYear W28955822362023 @default.
• W2895582236 crossrefType "journal-article" @default.
• W2895582236 hasAuthorship W2895582236A5008924495 @default.
• W2895582236 hasAuthorship W2895582236A5014077632 @default.
• W2895582236 hasAuthorship W2895582236A5017526826 @default.
• W2895582236 hasAuthorship W2895582236A5017774152 @default.
• W2895582236 hasAuthorship W2895582236A5019997274 @default.
• W2895582236 hasAuthorship W2895582236A5028189327 @default.
• W2895582236 hasAuthorship W2895582236A5051070911 @default.
• W2895582236 hasAuthorship W2895582236A5051375932 @default.
• W2895582236 hasAuthorship W2895582236A5057744438 @default.
• W2895582236 hasAuthorship W2895582236A5066378974 @default.
• W2895582236 hasAuthorship W2895582236A5073246708 @default.
• W2895582236 hasAuthorship W2895582236A5086555588 @default.
• W2895582236 hasAuthorship W2895582236A5088286120 @default.
• W2895582236 hasBestOaLocation W28955822361 @default.
• W2895582236 hasConcept C121608353 @default.
• W2895582236 hasConcept C126322002 @default.
• W2895582236 hasConcept C143998085 @default.
• W2895582236 hasConcept C2776530083 @default.
• W2895582236 hasConcept C2776833033 @default.
• W2895582236 hasConcept C2777506169 @default.
• W2895582236 hasConcept C2779438470 @default.
• W2895582236 hasConcept C2779998722 @default.
• W2895582236 hasConcept C31760486 @default.
• W2895582236 hasConcept C502942594 @default.
• W2895582236 hasConcept C509974204 @default.
• W2895582236 hasConcept C526805850 @default.
• W2895582236 hasConcept C535046627 @default.
• W2895582236 hasConcept C71924100 @default.
• W2895582236 hasConceptScore W2895582236C121608353 @default.
• W2895582236 hasConceptScore W2895582236C126322002 @default.
• W2895582236 hasConceptScore W2895582236C143998085 @default.
• W2895582236 hasConceptScore W2895582236C2776530083 @default.
• W2895582236 hasConceptScore W2895582236C2776833033 @default.
• W2895582236 hasConceptScore W2895582236C2777506169 @default.
• W2895582236 hasConceptScore W2895582236C2779438470 @default.
• W2895582236 hasConceptScore W2895582236C2779998722 @default.
• W2895582236 hasConceptScore W2895582236C31760486 @default.
• W2895582236 hasConceptScore W2895582236C502942594 @default.
• W2895582236 hasConceptScore W2895582236C509974204 @default.
• W2895582236 hasConceptScore W2895582236C526805850 @default.
• W2895582236 hasConceptScore W2895582236C535046627 @default.
• W2895582236 hasConceptScore W2895582236C71924100 @default.
• W2895582236 hasFunder F4320306095 @default.

• next